Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1981;64:823-831

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, D.
Right arrow Articles by Shieh, W. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, D.
Right arrow Articles by Shieh, W. B.

Circulation, Vol 64, 823-831, Copyright © 1981 by American Heart Association


ARTICLES

Effects of quinidine on atrioventricular nodal reentrant paroxysmal tachycardia

D Wu, JS Hung, CT Kuo, KS Hsu and WB Shieh

Electrophysiologic studies were performed in 14 patients with atrioventricular nodal reentrant paroxysmal tachycardia (PSVT) before and after oral administration of 1.2-1.6 g quinidine sulfate over a 24- hour period (0.3-0.4 g every 6 hours). Studies were performed after 0.5- 1 mg i.v. atropine before and after quinidine. All 14 patients had induction of sustained PSVT before quinidine, with or without atropine. After quinidine, 11 patients lost the ability to induce echoes or sustain PSVT, reflecting depression of the retrograde pathway with either absence of atrial echoes (six patients) or induction of nonsustained PSVT, with termination of echoes or PSVT occurring after QRS (block in retrograde pathway) (five patients). In only one of these 11 patients was sustained PSVT inducible after addition of atropine. All 11 were discharged on the same dose of quinidine. In three patients, quinidine was discontinued because of side effects. Follow-up in the remaining eight patients for 8 +/- 2 months showed no recurrence of sustained PSVT. Three of the 14 patients had induction of sustained PSVT after quinidine. Ventricular paced cycle length producing ventriculoatrial block was 314 +/- 7 msec (mean +/- SEM) before and 392 +/- 13 msec after quinidine (p less than 0.01) in the 14 patients, suggesting depression of the retrograde pathway with quinidine. In summary, quinidine inhibited induction of sustained atrioventricular nodal reentrant tachycardia with depression of the retrograde pathway. It is very effective in preventing recurrence of PSVT in most patients.


This article has been cited by other articles:


Home page
CirculationHome page
S.-A. Chen, C.-E. Chiang, C.-T. Tai, S.-H. Lee, C.-W. Chiou, K.-C. Ueng, Z.-C. Wen, C.-C. Cheng, and M.-S. Chang
Longitudinal Clinical and Electrophysiological Assessment of Patients With Symptomatic Wolff-Parkinson-White Syndrome and Atrioventricular Node Reentrant Tachycardia
Circulation, June 1, 1996; 93(11): 2023 - 2032.
[Abstract] [Full Text]


Home page
NEJMHome page
L. I. Ganz and P. L. Friedman
Supraventricular Tachycardia
N. Engl. J. Med., January 19, 1995; 332(3): 162 - 173.
[Full Text] [PDF]